China approves sugemalimab to treat unresectable NSCLC
Time : 16th of August 2022 02:33:26 PM
,
CStone Pharmaceuticals said that the NMPA of China approved the first anti-PD-1/PD-L1 monoclonal antibody, sugemalimab, for treating patients with unresectable non-small cell lung cancer (NSCLC) stage III whose disease did not progress after platinum-based chemoradiotherapy. Sugemalimab increased the overall survival rate in patients with NSCLC.
PR NewswireTags
sugemalimab, NSCLC, ChinaRecent Posts
Illicit drugs could be the reason behind 30% of sudden cardiac deaths
3rd of August 2023 02:58:31 PM
3rd of August 2023 02:58:31 PM
